Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Here's Why Reata Pharmaceuticals Skyrocketed Higher Today

By Brian Orelli, PhD - Oct 15, 2019 at 1:37PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Data from a phase 2 study looks promising.

What happened

Shares of Reata Pharmaceuticals ( RETA 11.24% ) are up 59% at 12:26 p.m. EDT, after the company released positive data for the midstage Moxie study of its drug candidate, omaveloxolone, in patients with a neuromuscular disease called Friedreich's ataxia.

As biotech investors have seen time and time again, positive clinical trial data can lead to monstrous one-day gains, especially if that data comes in a disease like Friedreich's ataxia where multiple failures over the years have led to low expectations.

Doctor examining a patient's leg

Image source: Getty Images.

So what

Using the modified Friedreich's Ataxia Rating Scale (mFARS), patients treated with omaveloxolone had an average improvement of 1.55 points -- improvement indicates a lower score on the scale -- compared to an average worsening of 0.85 points for patients who received placebo. The 2.4-point difference was statistically significant.

The clinical trial was set up to exclude patients with pes cavus, a musculoskeletal foot deformity that can keep patients from performing some of the tests in the mFARS exam. But even when patients with pes cavus were included, the difference in scores was 1.93 points, which was also statistically significant.

Importantly, the effect increased over time with 48 weeks -- the end of the study -- showing the largest mFARS improvement for omaveloxolone compared to placebo. Since this will be a long-term treatment, and not a cure, doctors will want to see that kind of robust, long-lasting effect.

Now what

In a well-timed move last week, Reata Pharmaceuticals agreed to pay $330 million to reacquire the rights to omaveloxolone and bardoxolone, a drug in the same Nrf2 activator drug class, from its partner AbbVie ( ABBV 0.30% ). Reata will also owe AbbVie single-digit, tiered royalties on sales of omaveloxolone and predefined next-generation Nrf2 activators, but bardoxolone will be royalty-free.

Reata will need to meet with the Food and Drug Administration and other regulators to discuss whether the data from Moxie is enough to gain approval. Given the unmet need for patients with Friedreich's ataxia, an accelerated approval with Reata performing a confirmatory post-marketing study seems likely -- but this is the FDA, and anything can happen.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Reata Pharmaceuticals, Inc. Stock Quote
Reata Pharmaceuticals, Inc.
$54.42 (11.24%) $5.50
AbbVie Inc. Stock Quote
AbbVie Inc.
$121.87 (0.30%) $0.36

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/08/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.